Kaiser Permanente researchers to study Vascepa in people 50 and older with heart disease.
The late-stage clinical trial will test the vaccine in 1,400 adults at 4 sites in California and Oregon.
Kaiser Permanente study published in the journal Gastroenterology supports starting screening at age 45 among this higher-risk population.
Clinical trials play a vital role in advancing cancer treatment at Kaiser Permanente, improving patients’ survival and quality of life.
Kaiser Permanente Northern California researchers say new as-needed PrEP regimen may increase use of the highly effective medication.